The FDA removed the partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab in ovarian and clear cell gynecologic cancers, allowing the trial to proceed. This regulatory clearance de-risks the program and should be a modest positive for MacroGenics' outlook and shares (potentially a ~1–3% stock move); monitor the company for protocol updates and revised timelines for the next data readouts.
The FDA removed the partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab in ovarian and clear cell gynecologic cancers, allowing the trial to proceed. This regulatory clearance de-risks the program and should be a modest positive for MacroGenics' outlook and shares (potentially a ~1–3% stock move); monitor the company for protocol updates and revised timelines for the next data readouts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
